These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 32265933)

  • 1. Single-Cell Approaches to Profile the Response to Immune Checkpoint Inhibitors.
    Gibellini L; De Biasi S; Porta C; Lo Tartaro D; Depenni R; Pellacani G; Sabbatini R; Cossarizza A
    Front Immunol; 2020; 11():490. PubMed ID: 32265933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
    Denis M; Duruisseaux M; Brevet M; Dumontet C
    Front Immunol; 2020; 11():492. PubMed ID: 32265935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical Treatment of Lung Cancer: Can Immune Cells Predict the Response? A Systematic Review.
    Rochigneux P; Garcia AJ; Chanez B; Madroszyk A; Olive D; Garon EB
    Front Immunol; 2020; 11():1036. PubMed ID: 32670271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring the immune competence of cancer patients to predict outcome.
    Chang S; Kohrt H; Maecker HT
    Cancer Immunol Immunother; 2014 Jul; 63(7):713-9. PubMed ID: 24487923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systems immune monitoring in cancer therapy.
    Greenplate AR; Johnson DB; Ferrell PB; Irish JM
    Eur J Cancer; 2016 Jul; 61():77-84. PubMed ID: 27155446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut microbiome and cancer immunotherapy.
    Sun JY; Yin TL; Zhou J; Xu J; Lu XJ
    J Cell Physiol; 2020 May; 235(5):4082-4088. PubMed ID: 31663125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue biomarkers of immune checkpoint inhibitor therapy.
    Davoudi F; Moradi A; Sadeghirad H; Kulasinghe A
    Immunol Cell Biol; 2024 Mar; 102(3):179-193. PubMed ID: 38228572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are there, or shall we discover, biomarkers to guide PD-1 inhibition?
    Ascierto PA; de Mello RA
    Immunotherapy; 2016 Jun; 8(6):681-6. PubMed ID: 27197537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune and metabolic checkpoints blockade: Dual wielding against tumors.
    Kazemi MH; Najafi A; Karami J; Ghazizadeh F; Yousefi H; Falak R; Safari E
    Int Immunopharmacol; 2021 May; 94():107461. PubMed ID: 33592403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-Cell Proteomics for Cancer Immunotherapy.
    Li L; Yan S; Lin B; Shi Q; Lu Y
    Adv Cancer Res; 2018; 139():185-207. PubMed ID: 29941105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostaglandin E Receptor 4 Antagonist in Cancer Immunotherapy: Mechanisms of Action.
    Take Y; Koizumi S; Nagahisa A
    Front Immunol; 2020; 11():324. PubMed ID: 32210957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From Oncogenic Signaling Pathways to Single-Cell Sequencing of Immune Cells: Changing the Landscape of Cancer Immunotherapy.
    Derakhshani A; Rostami Z; Safarpour H; Shadbad MA; Nourbakhsh NS; Argentiero A; Taefehshokr S; Tabrizi NJ; Kooshkaki O; Astamal RV; Singh PK; Taefehshokr N; Alizadeh N; Silvestris N; Baradaran B
    Molecules; 2021 Apr; 26(8):. PubMed ID: 33920054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-cell Analysis Technologies for Immuno-oncology Research: from Mechanistic Delineation to Biomarker Discovery.
    Bai Z; Su G; Fan R
    Genomics Proteomics Bioinformatics; 2021 Apr; 19(2):191-207. PubMed ID: 34000441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer.
    Noguchi E; Shien T; Iwata H
    Jpn J Clin Oncol; 2021 Mar; 51(3):321-332. PubMed ID: 33324990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer.
    Law AMK; Valdes-Mora F; Gallego-Ortega D
    Cells; 2020 Feb; 9(3):. PubMed ID: 32121014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors.
    Hou A; Hou K; Huang Q; Lei Y; Chen W
    Front Immunol; 2020; 11():783. PubMed ID: 32508809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of Immune checkpoint inhibitors benefit from routinely measurable peripheral blood parameters.
    Voutsadakis IA
    Chin Clin Oncol; 2020 Apr; 9(2):19. PubMed ID: 32279524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy.
    Zemek RM; Chin WL; Nowak AK; Millward MJ; Lake RA; Lesterhuis WJ
    Front Immunol; 2020; 11():223. PubMed ID: 32133005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
    Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
    Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy.
    Song Y; Li Z; Xue W; Zhang M
    Immunotherapy; 2019 Apr; 11(6):515-529. PubMed ID: 30860441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.